PCOS / PMOS · 6 min read · 2026-05-16
PCOS Has a New Name: PMOS. Here's What Changed (And What Didn't)
If you searched for "PMOS" and landed here wondering whether it's the same thing as PCOS — it is. In May 2026, a Lancet Commission of 90 international experts voted 87 to 3 to rename Polycystic Ovary Syndrome to Polyendocrine Metabolic Ovarian Syndrome. The new abbreviation is PMOS.
This is not a different condition. No new disease has been discovered. The condition itself — the hormonal and metabolic profile that affects an estimated 8–13% of women of reproductive age — is unchanged. What changed is the name, and the name change matters more than it might initially seem.
Names in medicine shape how conditions are understood, funded, researched, and treated. When a name is wrong — when it describes the condition poorly, excludes a significant portion of people who have it, or frames it in a way that leads to underdiagnosis or mismanagement — that name causes harm. The PCOS name had been causing that kind of quiet harm for decades. The rename is a correction.
Why the Name Changed: Four Problems With "PCOS"
The original name, Polycystic Ovary Syndrome, described what ultrasound imaging showed in the 1930s: ovaries with many small follicles (then called "cysts"). But the science has moved significantly beyond that observation, and the name hadn't kept pace.
First: "polycystic" is not only technically imprecise (the follicles aren't pathological cysts) but diagnostically misleading. Up to 20% of women diagnosed with PCOS don't have polycystic-appearing ovaries on ultrasound. They still have the condition — the hormonal and metabolic profile is present — but their ovaries don't match the name. This creates real confusion.
Second: "Ovary Syndrome" frames PCOS as primarily a reproductive or ovarian condition. It is not. PCOS involves multiple endocrine organs — the adrenal glands, the hypothalamic-pituitary axis, the pancreas — and has systemic metabolic effects including insulin resistance, elevated androgen production, and chronic low-grade inflammation. Limiting it to "ovary" has contributed to decades of under-treatment of its metabolic components.
Third: the word "syndrome" adds ambiguity. PMOS has a better-understood mechanism now, and the new name reflects that understanding.
What PMOS Actually Stands For
Polyendocrine Metabolic Ovarian Syndrome. Each word was chosen deliberately.
"Poly-endocrine" — multiple endocrine organs are involved. PMOS is not confined to the ovaries. The hypothalamic-pituitary axis has dysregulated GnRH pulsatility. The adrenal glands often contribute excess androgens. The pancreas produces excess insulin due to peripheral insulin resistance. This is a multi-system endocrine condition.
"Metabolic" — PMOS is a whole-body metabolic condition. Insulin resistance is present in 70–80% of people with PMOS. The associated risks — type 2 diabetes, cardiovascular disease, endometrial cancer — are metabolic risks. The most effective interventions — including metformin, inositol, lifestyle modification — target metabolic pathways. The new name finally reflects this reality.
"Ovarian" — the ovaries remain part of the name, appropriately, because ovarian androgen production and follicular development patterns are central to the condition. The name is more accurate, not an erasure of the ovarian component.
ICD code changes will roll out over approximately three years. Your doctor may still say PCOS for some time. Both names mean the same condition.
Does the Rename Change Treatment or Supplement Protocols?
No — the rename doesn't change the underlying biology, the diagnostic criteria, or the treatment approach. What may change over time is clinical emphasis: if providers think of PMOS as a polyendocrine metabolic condition rather than a "period problem," they may be more aggressive about screening for and treating insulin resistance, cardiovascular risk, and metabolic syndrome components. That shift in clinical framing is genuinely important for long-term health outcomes.
The supplement evidence base is unchanged. Myo-inositol remains the most evidence-backed nutritional supplement for PMOS, with strong data for improving insulin sensitivity, ovarian function, and cycle regularity. Vitamin D deficiency remains extremely common in PMOS and worth testing and correcting. Omega-3 addresses inflammation and cardiovascular risk. Magnesium supports insulin signaling and is commonly deficient.
What the rename underscores is that an effective supplement protocol for PMOS should address both the ovarian-hormonal and the metabolic layers. A protocol focused only on cycle regularity — without addressing insulin resistance and inflammation — is incomplete. The new name is a useful reminder of why the metabolic components matter.
What It Means for People Who Have PCOS / PMOS
If you've been diagnosed with PCOS, your diagnosis is still valid. The same diagnostic criteria apply (Rotterdam criteria require 2 of 3: irregular ovulation, clinical or biochemical hyperandrogenism, polycystic ovarian morphology on ultrasound). The new name doesn't require re-diagnosis.
What you can do with the new framing: push for comprehensive care that addresses the metabolic layer, not just the reproductive symptoms. If your provider has only ever discussed PMOS in terms of period regulation or fertility, ask about fasting insulin, lipid panel, cardiovascular risk screening, and metabolic monitoring. The name change is a natural opening for that conversation.
For people who were told "you don't have PCOS because your ovaries look normal on ultrasound" — the diagnostic criteria clarification may be an opportunity to revisit that assessment. Twenty percent of PMOS diagnoses don't require polycystic ovarian morphology; the other two Rotterdam criteria are sufficient for diagnosis.
Selene tracks this research because the hormonal-metabolic landscape of PMOS is directly relevant to cycle-aware supplementation. The rename reflects science we were already building around.
The bottom line
PCOS and PMOS are the same condition — the rename reflects scientific progress, not a new disease. The new name correctly identifies PMOS as a polyendocrine metabolic condition, not just an ovarian one, and that framing has real implications for how comprehensively it's treated. Selene's PMOS profile addresses both the hormonal and metabolic layers — inositol, vitamin D, omega-3, magnesium, and cycle-phase awareness — because the science supports treating the whole picture. Take the quiz to see your full protocol.
Questions
Does PMOS mean my PCOS diagnosis is no longer valid?
Your diagnosis is completely valid — PCOS and PMOS are the same condition, same diagnostic criteria, same treatment approach. The rename is a scientific reclassification for accuracy, not a change in the underlying condition. You don't need to be re-diagnosed, and your medical history doesn't change. ICD code transitions will occur gradually over the next few years; your medical records may carry the PCOS coding for some time, and both terms are correct during the transition period.
Why did the Lancet Commission vote to rename it now?
The push for renaming has been building in the medical literature for over a decade, but the Lancet Commission was the formal body that could coordinate an international consensus vote. Timing in 2026 reflects accumulated evidence that the original name was causing measurable harm — contributing to delayed diagnosis (the ovary-centric framing led some providers to dismiss PMOS diagnoses when ultrasounds looked "normal"), undertreatment of metabolic components, and stigma in communities where "polycystic" was misunderstood as cysts requiring surgery.
How should I explain PMOS to my doctor if they still use PCOS?
They're the same condition, and most providers will be aware of the rename — though adoption into clinical practice takes time. You can simply say "I have PCOS — I've also seen it's being renamed PMOS in the 2026 Lancet Commission" to acknowledge both. The more important conversation is whether your provider is addressing both the hormonal and the metabolic components. The name change is a natural opener for asking about insulin resistance screening, cardiovascular monitoring, and whether your care plan addresses the full polyendocrine metabolic picture.
What supplements are most evidence-backed for PMOS?
Myo-inositol is the most evidence-backed nutritional supplement specifically for PMOS — it improves insulin sensitivity, reduces androgen levels, and supports ovarian function and cycle regularity in multiple RCTs. Vitamin D3 is important because deficiency is highly prevalent in PMOS and worsens insulin resistance. Omega-3 addresses the cardiovascular and inflammatory risk that comes with the metabolic component. Magnesium is commonly deficient in PMOS and supports insulin signaling. Together, these address both the hormonal and metabolic layers that the new name correctly identifies as central to the condition.
Build an evidence-based PCOS / PMOS protocol.
Selene's personalization engine maps your hormonal profile to peer-reviewed ingredient stacks, adjusted for your cycle phase and symptom cluster.
View the PCOS / PMOS clinical profile →